| Evoke Pharma is a pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. Co. is developing Gimoti, an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Diabetic gastroparesis is a GI disorder is characterized by slow or delayed gastric emptying and evidence of gastric retention in the absence of mechanical obstruction and can cause various serious digestive system symptoms and other complications. Metoclopramide tablets and injection are the products approved in the U.S. to treat the symptoms associated with diabetic gastroparesis. We show 29 historical shares outstanding datapoints in our EVOK shares outstanding history coverage, used to compute EVOK market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EVOK market cap history over the course of time is important for investors
interested in comparing EVOK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EVOK versus a peer is one thing; comparing
EVOK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EVOK can fluctuate over the course of history.
With this page we aim to empower investors researching EVOK by allowing them to research the EVOK market cap history.